NEWS | BEAM Alliance


Phage futures Europe: Translating phage-based applications into clinically and commercially viable therapeutics

Date: November 23-24
Venue: Pullman Brussels Centre Midi, Place Victor Horta 1, 1060 Bruxelles, Belgium

This year’s Phage Futures Europe, taking place in Brussels on 23-24 November, will address these challenges by showcasing clinical trial data presentations from the likes of Locus Biosciences, BiomX, Eligo Bioscience and many more. Join  to understand the current clinical and commercial landscape surrounding phage with expert speaker line-up, including:
Mathew Tebeau, Chief Operations Officer, Proteon Pharmaceuticals will highlight the key market considerations to enable you to bring a phage product to the market globally.
Dr. Edith Hessel, CSO, Eligo Bioscience identifies the application of phages in the skin microbiome to addresses the emerging pharmaceutical regulatory standards.
– Identify how the progression and development of crPhage is enabling E. coli targeting in urinary tract infections with clinical data from Dr. Dave Ousterout, Chief Scientific Officer, Locus Biosciences.

More information available here.